Jeffrey LeVee, a partner in Jones Day's Antitrust & Competition Law Practice and head of litigation in the Los Angeles Office, and Daniel McMillan, a leader in the Firm's global construction practice and a member of the Business & Tort Litigation Practice also in the Los Angeles Office, have been named to the Los Angeles Business Journal's list of "Leaders of Influence: Litigators & Trial Attorneys." The editors select lawyers based on a demonstration of their ability "to go to the proverbial mat to fight for their clients."
Mr. LeVee focuses on antitrust litigation, health care litigation, and complex business and antitrust counseling. He was lead counsel for RE/MAX in a recent series of antitrust cases involving brokerage fees in the residential real estate market and forged RE/MAX's settlement of the cases weeks before the first trial. He has successfully litigated and arbitrated matters in courts and other administrative bodies throughout the United States. The clients he represents include health care providers, pharmaceutical companies, retailers, telecommunications companies, manufacturers, and technology companies.
Mr. McMillan focuses his practice on the construction industry for Fortune 500 project owners and developers, contractors, and public entities who seek his advice on the largest, most complex and challenging projects located in California, throughout the United States, and across the globe.
Recently he acted as the lead trial counsel in an ICC arbitration in New York concerning the design and construction of a large LNG facility located in southwest Louisiana—successfully recovering more than $200 million for the EPC contractor and defeating the owner's claim of more than $1 billion for alleged mismanagement.
He also has represented Los Angeles County Metropolitan Transportation Authority (Metro) for over 30 years, and is currently representing Metro in transportation projects amounting to more than $7 billion that are set to be completed in advance of the 2028 LA Summer Olympics.
We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.